Abstract | The defining feature of the Gram-negative cell envelope is the presence of two cellular membranes, with the specialized glycolipid lipopolysaccharide (LPS) exclusively found on the surface of the outer membrane. The surface layer of LPS contributes to the stringent permeability properties of the outer membrane, which is particularly resistant to permeation of many toxic compounds, including antibiotics. As a common surface antigen, LPS is recognized by host immune cells, which mount defences to clear pathogenic bacteria. To alter properties of the outer membrane or evade the host immune response, Gram-negative bacteria chemically modify LPS in a wide variety of ways. Here, we review key features and physiological consequences of LPS biogenesis and modifications.
Molecules at the surface of bacterial cells perform crucial roles of interacting with and reacting to the surrounding environment. The surface of Gram-negative bacteria is composed of an asymmetric outer membrane that contains the glycolipid lipopolysaccharide (LPS) exclusively on its outer leaflet 1 . The asymmetric distribution of LPS on the surface produces a potent barrier that is impermeable to many toxic compounds, including antibiotics 2 . To maintain the asymmetry and permeability properties of this unique barrier, most Gram-negative bacteria have dedicated pathways for removing glycerophospholipids that are mislocalized to the outer leaflet. In addition, as a major constituent of the outer membrane, LPS is essential in most Gram-negative bacteria (Box 1) and is critical for virulence 3 . LPS synthesis occurs at the cytoplasmic interface of the inner membrane, and then LPS is transported across the inner membrane to the outer membrane 4, 5 ( Fig. 1a) . LPS can be divided into three regions: the conserved lipid A anchor, core oligosaccharide and O antigen. The conserved lipid A unit is a bisphosphorylated disaccharide of glucosamine (GlcN) typically with four to seven acyl chains (Fig. 1b) . LPS synthesis begins with the Raetz pathway (Fig. 1a) , a series of conserved enzymatic steps that produce lipid A with 3-deoxy-d-manno-oct-2-ulosonic acid (Kdo) sugars, the first units of the core oligosaccharide. Briefly, with the model organism Escherichia coli as an example, the Raetz pathway starts with the precursors UDP-N-acetylglucosamine (UDP-GlcNAc) and acyl carrier protein-bound fatty acids. The successive actions of the acyltransferase LpxA, the deacteylase LpxC and the acyltransferase LpxD produce UDP-2,3-diacylglucosamine 3 . The first reaction, involving LpxA, is unfavourable, and deacetylation by LpxC is the first committed step of synthesis 3 , leading to UDP-2,3-diacylglucosamine. From some of the UDP-2,3-diacylglucosamine, a UMP is cleaved to produce 2,3-diacylglucosamine 1-phosphate, also named lipid X 3 . Lipid X production relies on one of three non-homologous enzymes: LpxH in E. coli and most Gram-negative bacteria, LpxI in alphaproteobacteria 3 and LpxG in members of the phylum Chlamydiae 6 . LpxB then catalyses the formation of a β-1′-6 glycosidic bond between one molecule of lipid X and one molecule of UDP-2,3-diacylglucosamine, which releases the UDP nucleotide carrier 3 . LpxK then phosphorylates the tetra-acylated 1-phosphorylated reaction product at the 4′ position to produce lipid IV A (reF.
3
). This is followed by the addition of the Kdo sugar(s), the number of which differs in different bacteria, by the enzyme WaaA (also known as KdtA) 3 . Finally, two acyltransferases, LpxL and LpxM, catalyse the transfer of 'secondary' acyl chains, completing the Kdo-lipid A domain of LPS 3 . Most bacteria encode homologues of LpxL; however, many bacteria, such as Francisella spp., do not encode an LpxM homologue, and others encode distinct acyltransferases instead of LpxM, such as LpxJ in many epsilonproteobacteria 7 and LpxN in Vibrio cholerae 8 . Next, the core oligosaccharide is extended at the cytoplasmic side of the inner membrane (not covered here), producing lipooligosaccharide (LOS). Some bacteria, including a number of mucosal pathogens, produce only LOS 3 . O-antigen precursors, if produced, are synthesized separately on the cytoplasmic side of the inner membrane and are attached to the lipid carrier undecaprenyl pyrophosphate 3 . MsbA 2 and an O-antigen flippase (these differ depending on the bacterium) then flip LOS and O-antigen precursors across the inner membrane, respectively 3 . Depending on the O-antigen biosynthesis pathway, O antigen is polymerized either before flipping or at the periplasmic leaflet of the inner membrane 3 . In both scenarios, O antigen is appended to LOS in the periplasm 3 . The Lpt (LPS transport) machinery then transports LPS or LOS to the surface of the outer membrane 9 (Fig. 1a) .
LPS properties affect outer membrane permeability, resistance to antibiotics, virulence and recognition by the host immune system. Thus, bacteria have evolved many enzymes that modify LPS to alter its properties and allow them to adapt to the dynamic environments they inhabit. In this Review, we provide an up-to-date overview of LPS biogenesis and its modification. We highlight recent insights into how LPS modifications affect host immune responses and the formation of bacterial outer membrane vesicles (OMVs). Finally, we discuss how a mechanistic understanding of LPS biogenesis and remodelling has led to the development of antibacterial therapeutics.
Altering LPS LPS biogenesis is the first opportunity for the introduction of variation into the LPS structure. Below, we compare different lipid A variants with the lipid A anchor that E. coli K-12 produces under standard laboratory conditions (Luria-Bertani broth at 37 °C, Fig. 1b ). Under these conditions, the lipid A disaccharide of GlcN has two attached Kdo sugars and is bisphosphorylated and hexa-acylated. The GlcN disaccharide has two primary N-linked β-hydroxyacyl chains at the 2 and 2′ positions and two primary O-linked β-hydroxyacyl chains at the 3 and 3′ positions. E. coli lipid A also has two secondary acyl chains attached to the β-hydroxyl groups of the 2′ and 3′ acyl chains.
Variations to LPS introduced during the Raetz pathway alter either the sugars or the acyl chains of the Kdo-lipid A domain (Supplementary Table 1 and Supplementary Fig. 1 ). Alterations to the sugars GlcN and Kdo can occur before incorporation into lipid A. Bacteria such as Campylobacter jejuni and Leptospira interrogans use the enzymes GnnA and GnnB to oxidize and transaminate UDP-GlcNAc, respectively, converting it into the 3-amino derivative 2,3-diamino-2,3-dideoxy-d-glucopyranose 10, 11 . These bacteria encode LpxA homologues that selectively use the modified 2,3-diamino-2,3-dideoxy-d-glucopyranose 10 . The resulting lipid A has four amide-linked acyl chains, which reduce recognition by host immune cells and sensitivity to antimicrobials 11 . Similarly, the enzymes KdnA and KdnB in Shewanella spp. modify Kdo to produce an eight-amino derivative, 8-amino-3,8-dideoxy-d-mannooctulosonic acid (Kdo8N) 12 . Kdo8N is then activated to its nucleotide-linked form and feeds into lipid A synthesis as a substrate of WaaA. Kdo8N-containing LPS was also found to have a protective role against antimicrobials 12 . In addition to modifications of sugar precursors, variations to Kdo incorporated into lipid A can occur during or after the Raetz pathway. WaaA variants of different bacteria differ in the number of Kdo sugars (one, two, three or four) they attach [13] [14] [15] [16] . Many bacteria can also hydroxylate (via KdoO) 17 or phosphorylate (via KdkA) 14, 18 Kdo during lipid A synthesis. Bacteria that alter GlcN and Kdo during the Raetz pathway do so constitutively.
In addition, variation in the substrate selectivity of the Lpx acyltransferases in different bacteria changes fatty acyl chain characteristics, such as length, saturation and branching. Furthermore, the secondary acyltransferases, LpxL and LpxM, can differ in the position of acyl chain attachment and in the number of transferred acyl chains (Supplementary Table 1 ). LpxM from Acinetobacter baumannii, for example, is bifunctional and transfers a laurate to the 2 and 3′ acyl chains 19 . In addition, many organisms will alter the acyl chains incorporated into lipid A in response to environmental conditions by encoding more than one enzyme that acts at the same position (Supplementary Table 1 ). This type of variation is well known for bacteria such as Salmonella enterica subspp. and E. coli that express LpxL, a lauroyl (C12:0) transferase, at high temperatures and LpxP, a palmitoleoyl (C16:1) transferase, at low temperatures 3 . In addition, Klebsiella pneumoniae encodes two LpxL homologues, LpxL1 and LpxL2, that are coexpressed under standard growth conditions and compete to add at the same position either a lauroyl (C12:0) group or a myristoyl (C14:0) group, respectively. Finally, organisms such as Leptospira interrogans and Francisella tularensis encode two homologues of LpxD (Fig. 1a) that incorporate acyl chains of different length 20, 21 . In F. tularensis, [129] [130] [131] . However, only A. baumannii strains can inactivate lipid A synthesis in a selectable manner to provide resistance to cationic antimicrobial peptides, including polymyxin antibiotics 129 . loss of lipooligosaccharide (loS) in A. baumannii comes with fitness costs, reduces growth rate and virulence and increases sensitivity to many other antibiotics 132 . However, some clinical isolates are capable of inactivating lipid A synthesis, suggesting that this extreme mechanism of resistance could occur in hospitals or patients 129 . Furthermore, screening for this type of colistin resistance during treatment is needed to determine the clinical relevance. Work on loS-deficient A. baumannii has started to unravel how a bacterium can survive when lipid A synthesis is inactivated. A comparison of the ability of several strains of A. baumannii to inactivate loS synthesis found that peptidoglycan synthesis is a critical factor; loS-deficient mutants could be isolated from strains with low protein levels of penicillin-binding protein 1A (PBP1A) or with disruption of the gene encoding PBP1A, ponA, but not from strains expressing higher levels of PBP1A 133 . Furthermore, loSdeficient A. baumannii strains respond by increasing transcription of genes encoding the lipoprotein transporter and surface-exposed lipoproteins 133, 134 . These results indicate peptidoglycan synthesis and lipoprotein synthesis affect the ability of A. baumannii to survive with an outer membrane consisting of a symmetric glycerophospholipid bilayer. Furthermore, a short-term evolution experiment demonstrated that loS-deficient bacteria can increase overall fitness by inactivating genes required for the removal of glycerophospholipids from the outer leaflet of the outer membrane 135 .
As loS-deficient A. baumannii cells need to fill the outer leaflet with glycerophospholipids, it is logical that enzymes that remove or degrade these lipids in the outer leaflet would be disadvantageous. Specifically, mutations that result in disruption of the mla transporter, which transports mislocalized outer membrane glycerophospholipids back to the inner membrane, disruption of the phospholipase PldA, which degrades mislocalized glycerophospholipids, or disruption of both increases the growth rate of loS-deficient A. baumannii strains 135 . Disruption of mla and PldA is expected to allow accumulation of glycerophospholipids in the outer leaflet, replacing loS. These studies have demonstrated that loS biogenesis is interconnected with the biogenesis of other cell envelope components (peptidoglycan, outer membrane lipoproteins and outer membrane glycerophospholipids), and rewiring these connections is necessary for growth in the absence of loS. It remains unclear why lipid A synthesis is essential in some bacteria and not in others; however, loS-deficiency in A. baumannii has provided unique insights into cell envelope biology.
Outer membrane vesicles LpxD1 and LpxD2 expression and thus acyl chain length depend on temperature 21 , but the conditions under which L. interrogans expresses LpxD2 remain elusive 20 . After the Raetz pathway, LPS can be further modified by diverse enzymes that generally alter the acyl chains, the phosphate groups, the sugar backbone of lipid A and the core oligosaccharide (Fig. 1c,d and Supplementary Table 2 ). These modifications substantially influence lipid packing, membrane permeability, host recognition and sensitivity to antimicrobials (see later). Alterations to acyl chains of LPS after synthesis typically involve either addition or removal of fatty acids by enzymes in the outer membrane, such as LpxR, PagL and PagP [22] [23] [24] . These modifications enable bacteria to control the membrane characteristics of LPS that has already been transported to the surface. Other alterations to acyl chains of lipid A can occur at the inner membrane, including hydroxylation by the enzyme LpxO 25 , or, in the unique case of V. cholerae, addition of glycine moieties by AlmG 26 . Bacteria have evolved a plethora of strategies to alter the charge of lipid A. Briefly, many bacteria, such as Helicobacter pylori, cleave the phosphates from lipid A to produce a neutral or less negatively charged version than the uncleaved version (Fig. 1d) . The negative charge of lipid A can also be reduced by masking of phosphates with positively charged constituents, such as phosphoethanolamine (by EptA) 27 and 4-aminoarabinose (by ArnT) 27 , or neutral constituents, such as glucose sugars (by FlmK) 28 . By contrast, many bacteria use the enzyme LpxT to append additional phosphates to lipid A 29, 30 , increasing the negative charge. In addition, Kdo and the core oligosaccharide can be modified by addition of charged moieties, such as phosphates or phosphoethanolamine, or addition or removal of sugars 27 (Supplementary Table 2 ). Finally, Gram-negative bacteria encode a diversity of biosynthetic and modification enzymes that can alter the structure of O antigen that have been reviewed thoroughly elsewhere 31, 32 .
Regulation of LPS modifications LPS modification enzymes can be either constitutively expressed or controlled by regulatory networks. The human-adapted gastric pathogen H. pylori, for example, constitutively expresses a highly ordered repertoire of lipid A-modifying enzymes that produce a tetraacylated lipid A anchor with reduced phosphorylation [33] [34] [35] [36] (Fig. 1d ). However, in S. enterica subsp. enterica serovar Typhimurium, a wide range of regulatory mechanisms fine-tune when and to what extent LPS is modified to accommodate the bacterium's diverse lifestyle ( Fig. 2 and Supplementary Table 3) .
Many bacteria use two-component systems (TCS) to regulate LPS modification enzymes (Supplementary Table 3 ). At their core, these regulation systems consist of a sensor kinase that responds to a signal through autophosphorylation of a histidine residue. The phosphate is then transferred to a cognate response regulatory protein acting as a phosphorylation-mediated switch, turning on and off gene expression. PhoPQ and PmrAB are the most widespread TCS that affect lipid A modification genes 37, 38 . Here we briefly touch on the mechanism of these TCS, with a focus on recent advances.
PhoPQ is best studied in S. Typhimurium, in which it responds to many environmental stimuli, including acidic pH, low concentrations of divalent cations, antimicrobial peptides (AMPs) and most recently reported osmotic shock [38] [39] [40] [41] . The breadth of stimulating signals for PhoPQ differs between different bacteria 42 . However, studies of PhoQ in S. Typhimurium and E. coli have revealed how various signals can feed into one sensor (Fig. 2) .
PhoQ contains cytoplasmic, transmembrane and periplasmic domains. The periplasmic sensing domain has a patch of acidic residues close to the membrane surface that is crucial for sensing divalent cation concentrations and cationic AMPs 43 . Mg 2+ and Ca 2+ are thought to reduce repulsion between the acidic residues of PhoQ and the acidic head groups of glycerophospholipids in the inner membrane and favour PhoQ in an off conformation 43 . Repulsion in the absence of divalent cations or disruption of this bridging by binding of cationic AMPs to this site causes a conformational change that favours autophosphorylation 43 . Initially, it was thought that pH changes may also activate PhoQ through the periplasmic sensor domain 44 . However, recently it was suggested that the cytoplasmic domain senses pH changes. Mutations in the cytoplasmic domain abrogated sensing of pH changes but had no effect on sensing of Mg 2+ limitation 45 . Additionally, there is evidence that the inner membrane protein UgtL in S. Typhimurium binds PhoQ and amplifies the autophosphorylation in response to acidic pH 46 . Finally, high osmolarity was proposed to activate PhoQ by increasing lateral pressure exerted by lipids on the transmembrane domains of PhoQ, causing a change in the protein conformation 41 . Together, studies on PhoQ in S. Typhimurium have demonstrated the intricacies of how a senor kinase can be adapted for multiple stimuli. Activated PhoQ phosphorylates PhoP, which in S. Typhimurium and other bacteria transcriptionally regulates many virulence pathways, including lipid A modifications. PhoP directly regulates the genes pagL and pagP, but also indirectly affects other genes involved in LPS modification through regulation of small rNAs (sRNAs; discussed below) and the protein PmrD 22, 47, 48 . S. enterica subspp. and E. coli encode the protein PmrD, which mediates coupling between PhoPQ and PmrAB 48, 49 . When upregulated by activation of PhoPQ, PmrD binds to phosphorylated PmrA and protects it from being deactivated through the phosphatase activity of PmrB 50 . Thus, PhoPQ activation can indirectly feed into PmrAB regulation of genes such as arnT and eptA 37 . To control the extent of PhoPQ activation, PhoP also upregulates expression of MgrB, an inner membrane protein that provides negative feedback, closing the PhoPQ regulatory circuit 51 . PmrB is the sensor kinase in the PmrAB TCS, and binding of Fe
3+
, Al 3+ and in some organisms Zn 2+ to its periplasmic, metal-binding ExxE motif directly activates it 52 . Acidic pH can also activate PmrAB, but full activation requires both PmrB and PmrD, suggesting part of the activation involves PhoPQ 53 . The proposed pH sensing domain of PmrB consists of His and Glu residues in the periplasm, which may react to altered protonation states 53 . Activation of PmrB causes it to phosphorylate Small RNAs (srNAs). Typically short, noncoding rNA molecules that interact with mrNAs to regulate gene expression or interact with proteins to regulate activity.
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PmrA, which directly upregulates modification of aminoarabinose (arn operon) and phosphoethanolamine (eptA). Activation also increases transcription of the small protein PmrR, which binds to and inhibits activity of the lipid A phosphotransferase LpxT 54 . LpxT and EptA competitively modify the same site on LPS (Fig. 1c) ; therefore, LpxT inhibition increases phosphoethanolamine modification of lipid A by EptA driving AMP resistance 29 . Furthermore, the combined effects of PmrR, EptA and ArnT form a feedback loop that controls the level of PmrAB activation 54 . Activation of PmrAB by metal ions such as Fe 3+ depends on the charge of the outer membrane. Bacteria with a highly negatively charged outer membrane, due in part to the presence of LPS with bisphosphorylated and trisphosphorylated lipid A, experience high entry of Fe 3+ into the cell, where it activates PmrB. Activation of the PmrAB regulon stimulates the production of Arn proteins, EptA and PmrR. PmrR quickly inhibits LpxT, reducing the amount of trisphosphorylated lipid A produced and somewhat reducing the negative charge of the outer membrane. Production of aminoarabinose-modified and phosphoethanolaminemodified lipid A further reduces the negative charge of the outer membrane. As the charge of the cell surface becomes more positive, less Fe 3+ reaches PmrB, and activation is fine-tuned 54 . In addition to PhoPQ and PmrAB, bacteria can have other TCS that allow them to respond to environmental signals (Supplementary Table 3 ). Demonstrated in S. enterica subsp. enterica serovar Enteritidis but likely more widespread, the ArcAB TCS is one of the regulators that responds to oxygen availability and regulates the gene encoding LpxO, the oxygenase responsible for hydroxylation of a lipid A acyl chain 55 . Pseudomonas aeruginosa, for example, contains PhoPQ, PmrAB and three additional TCS that regulate lipid A modification genes. Its ColRS system senses Zn 2+ and specifically upregulates EptA, but not ArnT 56 . By contrast, ParRS and CprRS of P. aeruginosa sense AMPs and specifically upregulate ArnT 57, 58 . Whereas both sensor kinases of these systems, ParS and CprS, are activated by polymyxins, CprS is also activated by indolicidin and other peptides, enabling P. aeruginosa to respond to many environmental signals 57, 58 . V. cholerae also has an additional TCS, VprAB (also named CarRS), which senses bile, AMPs and acidic pH to regulate its almEFG operon, which modifies lipid A with glycine 59, 60 . Finally, some strains of K. pneumoniae have an additional TCS, CrrAB, that indirectly affects LPS modifications by upregulating CrrC, which in turn upregulates PmrAB 61 . Stimuli that activate CrrAB have yet to be determined. These examples demonstrate the breadth with which TCS regulate LPS modifications.
sRNAs commonly have connections to TCS and can either directly or indirectly regulate lipid A modification genes (Supplementary Table 3 ). MicA, an sRNA that represses synthesis of key outer membrane proteins, also negatively regulates PhoPQ expression at the post-transcriptional level, thereby influencing LPS structure as well 62 . PhoPQ upregulates the sRNA MgrR 63 . In turn, MgrR inhibits transcription of the eptB gene, which encodes a phosphoethanolamine transferase that modifies the second Kdo sugar of the core oligosaccharide 63 . As activation of PhoPQ typically leads to decoration of lipid A, MgrR inhibition of eptB expression is counterintuitive but further highlights the complex regulation of LPS modifications. The description of the TCS and sRNAs here is not a comprehensive overview of all factors that affect transcription or translation of LPS modification genes. Other sRNAs and transcriptional regulators are listed in Supplementary Table 3 .
Transcriptional regulation of outer membranes enzymes, such as PagP, PagL and LpxR, is a relatively slow process as it depends on assembly and turnover. To more tightly control their activity, these enzymes are also regulated at the level of recognition or availability of their substrates (Supplementary Table 3 ). LpxR of Yersinia enterocolitica and PagL of S. Typhimurium both poorly recognize lipid A that has been decorated with aminoarabinose 64, 65 . These deacylases can modify lipid A with unmodified phosphates, but their activity is repressed when aminoarabinose modification at the inner membrane is upregulated 64, 65 . PagP activity is instead regulated by the availability of its donor substrate. PagP has a role in maintaining the asymmetry of the outer membrane by transferring an acyl chain from the glycerophospholipid phosphatidylethanolamine to lipid A 66 . In S. enterica subspp. and E. coli, the activity of PagP is usually low because the outer leaflet of the asymmetric outer membrane lacks glycerophospholipids 2 . Upon membrane disruption, such as in Mg 2+ -limiting conditions or exposure to AMPs, glycerophospholipids flip to the outer leaflet, resulting in PagP-dependent acylation of lipid A 67 . These examples demonstrate some of the ways in which LPS modification enzymes are regulated post-translationally.
Consequences of LPS modifications
LPS modifications affect many physiological processes in Gram-negative bacteria. Below, we briefly review effects on the permeability of the outer membrane, recognition by immune cells, antimicrobial resistance and formation of OMVs (Fig. 3) .
Adaptation of outer membrane permeability.
Environmental factors, such as temperature, metal ion concentrations, pH, and AMPs, regulate LPS modifications, which affects not only pathogenesis but also outer membrane permeability. Mg 2+ bridging of the phosphates on lipid A and/or phosphates of the core oligosaccharide of LPS helps stabilize the outer membrane. In Mg 2+ -limiting conditions, however, the phosphates of LPS repel each other, decreasing outer membrane stability 68 . Through PhoPQ and PmrAB, bacteria such as S. enterica subspp. respond by upregulating PagP, ArnT and EptA, which help to stabilize the membrane by producing more hepta-acylated lipid A (decreasing fluidity) and adding positively charged moieties (aminoarabinose and phosphoethanolamine) to the 1-phosphate and the 4′-phosphate 68 . It is not fully clear how having predominantly positively charged lipid A, which would also charge clash, results in the formation of a more stable outer membrane than having predominantly negatively charged lipid A. Perhaps, because the positively charged moieties are attached to phosphate groups, the zwitterionic nature of modified lipid A allows crossbridging to occur between neighbouring molecules in the membrane. Alternatively, as PagP activity indicates that some glycerophospholipids are mislocalized to the outer leaflet, perhaps anionic glycerophospholipids (for example, phosphatidylglycerol) contribute to crossbridging positively charged lipid A species. Still, when Mg 2+ concentrations are high, constitutive expression of PagP, ArnT and EptA increases outer membrane permeability 68 , indicating that a negatively charged lipid A domain increases bacterial fitness in the presence of divalent cations. Thus, bacteria use different lipid A anchors in different environments to regulate outer membrane permeability.
Evading immune system recognition. The human immune system recognizes and responds to LPS as a common molecular signature of bacteria. LPS and LOS stimulate immune cells by binding to surface receptors or to a non-canonical inflammasome complex if internalized. Surface recognition starts with binding of LPS or LOS to LPS-binding proteins and CD14 (either soluble or membrane bound) and then transfer of the molecule t o T ol llike receptor 4-myeloid differentiation factor 2 (TLR4-MD2) complexes on immune cells 69 . Hexa-acylated, bisphosphorylated lipid A strongly activates TLR4-MD2 (reFS 70,71 ) (Fig. 3a) . The downstream signalling pathway depends on the adaptor proteins that are then recruited (Fig. 3a) . Recruitment of myeloid differentiation primary response protein 88 (MYD88) results in the MYD88-mediated pathway and production of proinflammatory cytokines. Meanwhile, recruitment of Toll-interleukin 1 domain-containing adaptor-inducing interferon-β (TRIF) results in the MYD88-independent pathway and low inflammation 72 . LPS modifications, especially those that remove the phosphates or alter the acylation of lipid A, can reduce either recognition by TLR4-MD2 or change which signalling pathway is triggered 70 www.nature.com/nrmicro a dephosphorylated, tetra-acylated form of lipid A that promotes immune evasion and long-term colonization of the gastric mucosa 74 . Due to differences in modifications and acylation of lipid A, H. pylori is 100-fold to 1000-fold less immunostimulatory than E. coli 74, 75 . In addition, many bacteria upregulate lipid A modifications during infection to evade TLR4-MD2 recognition. Intriguingly, a recent study 76 showed upregulation of lipid A modifications in K. pneumoniae directly isolated from infected tissue. This new approach allowed direct testing of which lipid A modifications are key for immune evasion in specific tissues. Modified LPS forms 
that have desired immunostimulatory effects have also been explored as therapeutics (Box 2).
LPS that is internalized by host cells, especially from intracellular pathogens, binds to caspases (caspases 4 and 5 in humans 77 , and caspase 11 in mice 78, 79 ) that then stimulate the inflammasome (Fig. 3a) . LPS stimulation of the inflammasome triggers an inflammatory cell lysis pathway called pyroptosis 80 . Similarly to TLR4 recognition, lipid A is the minimal unit required for inflammasome stimulation [77] [78] [79] . Reduced acylation of lipid A reduces recognition by murine caspase 11 (reFS 78, 79 ) but not by human caspase 4 or 5 (reF.
81
), indicating that these LPS modifications could be crucial for pathogenesis in certain mammalian hosts. Further work is needed to determine if other LPS modifications, especially those used by intracellular pathogens, allow evasion of inflammasome recognition in their natural hosts.
Resistance to AMPs. AMPs are part of the host immune response and non-specifically clear bacteria. In addition, Gram-positive bacteria naturally produce the cationic polymyxin AMPs, which have been adapted as antibiotics. AMPs are amphipathic; a typically cationic peptide mediates interaction with negatively charged LPS and a hydrophobic domain inserts itself into membranes, forming pores 82 (Fig. 3b) . Perforation of the outer membrane allows entry and disruption of the inner membrane, resulting in cell lysis 82 . LPS modifications that remove or modify the phosphates of lipid A, modify the phosphates of the core oligosaccharide and alter the acylation of lipid A can protect against AMPs (Fig. 3b and Supplementary Table 2) .
Recently, it was demonstrated that LPS modifications that provide resistance to AMPs contribute to long-term maintenance of commensal bacteria. The gut microbiota is a complex population of bacteria that are maintained long term, despite the mammalian immune response 83 . Specifically, several Bacteroidetes thetaiotaomicron commensal isolates were demonstrated to have high resistance to polymyxin B, which depended on the lipid A phosphatase LpxF 84 . Furthermore, in comparison of the ability of isogenic strains with and without LpxF to colonize the mouse gut and persist after inflammation, both B. thetaiotaomicron strains could colonize, but the strain without LpxF was displaced by inflammation 84 . This finding indicates that lipid A modifications can contribute to long-term maintenance of commensal gut bacteria. Although AMP resistance is a favourable trait for maintaining commensal bacteria, commensals can also become opportunistic pathogens, and AMP resistance would make them more resistant to clearance.
Polymyxins are considered 'last-resort' antibiotics due to toxicity. Still, with the increasing frequency of multidrug-resistant bacteria, their use has become necessary. Many pathogenic bacteria can become resistant to polymyxins through mutations that increase expression of chromosomally-encoded LPS-modifying enzymes such as mutations in pmrAB that result in increased levels of the Arn proteins and EptA 37 . Fortuitously, these types of mutations do not easily spread between bacteria. However, eptA homologues, named mcr genes for mobile colistin resistance, are encoded on plasmids and phages, which can spread more easily 85 . In the few short years since the first report, mobile homologues of eptA have been identified in many pathogenic bacteria and have been detected worldwide, leading to concerns about spread of resistance to even last-resort antibiotics 85 . These findings only increase the insurmountable evidence that new therapeutics are desperately needed. Notably, other LPS modifications that require one enzyme and no special precursors, such as dephosphorylation by LpxF, could also rapidly spread in a similar manner.
Effects on outer membrane vesicles. Gram-negative bacteria shed OMVs containing LPS as they grow. These OMVs are proposed to have roles in cell stress responses, nutrient acquisition and pathogenesis 86 . As LPS is a major constituent, altering LPS characteristics will also affect OMV processes, including recruitment of cargo proteins and vesicle production. Pathogens ). mPl adjuvant shows reduced activation of the myeloid differentiation primary response protein 88 (mYD88)-dependent response and thus induces less toxic inflammation 72 , while providing key adjuvant properties. To further fine-tune the lipid A-induced immune response, several groups [137] [138] [139] have bioengineered non-pathogenic bacteria to produce different lPS glycoforms by combinations of overexpressing and knocking out genes involved in lipid A synthesis and modification. In Escherichia coli 137 , altering the phosphates, number of acyl chains, position of acyl chains and acyl chain hydroxylation of lipid A individually or in combination can give a range of Toll-like receptor 4-myeloid differentiation factor 2 (TlR4-mD2) recognition and cytokine response. A similar range of immune stimulation was observed for lPS with modifications produced by Neisseria meningitidis 139 and Yersinia pestis 138 . Some lipid A species produced by E. coli or N. meningitidis showed different trends in TlR4-mD2 recognition, highlighting the importance of studying lPS-dependent immune modulation in different bacteria.
Altering lPS has also been used to increase the efficacy of outer membrane vesicle (omv) vaccines. omvs are successful vaccine platforms, particularly for N. meningitidis 140 , because they display molecular signatures of the pathogen but are unable to replicate. lPS modifications that stimulate omv formation or that alter the adjuvanticity have been combined with these platforms to have desired immunostimulatory effects. In addition, two groups [141] [142] [143] have developed methods to produce omvs that contain lPS with core oligosaccharide that are modified with pathogen-associated glycans (capsule, heterologous o antigens and other surface-displayed glycans). These approaches capitalize on the substrate promiscuity of the o-antigen ligase Waal, which can transfer a variety of sugar repeats from the undecaprenyl pyrophosphate carrier to lPS 3 . The genes for producing a desired pathogen-associated glycan are heterologously expressed in non-pathogenic E. coli K-12 strains that do not produce o antigen [141] [142] [143] . Waal appends the pathogenassociated glycan to lPS, and modified lPS is released in omvs. Since lPS in omvs is still endotoxic, the E. coli strains that produce these omv vaccines can be further engineered to have modified lipid A with reduced endotoxicity, while retaining adjuvant properties 142 . These vaccine platforms have been used to produce omvs displaying a variety of disease-associated glycans that upon immunization provide protection against the associated pathogen in disease models (for example, Streptococcus pneumoniae, Campylobacter jejuni, Francisella tularensis subsp. tularensis and N. meningitidis) [141] [142] [143] . Furthermore, displaying glycoengineered lPS on reducedendotoxic and commensal strains of E. coli instead of omvs could be promising as orally administrable, cost-effective, whole-cell vaccines.
Pyroptosis
An inflammatory, programmed cell death that typically is associated with infection of intracellular pathogens.
Capsule
A thick layer of polysaccharides that surrounds a bacterial cell, also referred to as capsular polysaccharide.
www.nature.com/nrmicro such as enterotoxigenic E. coli and Porphyromonas gingivalis produce virulence factors that bind to OMVs and are secreted into the environment 87, 88 . Recruitment of these factors to OMVs is driven by binding of the cargo proteins to the sugars of LPS at the cell surface (Fig. 3c) . Enterotoxigenic E. coli produces a heat-labile enterotoxin that binds to the Kdo sugars of the core oligosaccharide 88, 89 . Binding of labile toxin to LPS may be a mechanism of delivering the toxin on OMVs but it also partially sequesters the toxin at the outer membrane 89 . Research in P. gingivalis has revealed elaborate interactions between OMV proteins and specific LPS species. Early on, it was noted that LPS glycoforms with a negatively charged O antigen and a subset of key outer membrane proteins are enriched in OMVs 87 . Mutants that do not produce O antigen had OMVs with altered protein content, supporting a role in recruitment 87 . Furthermore, the proposed LPS modification gene lptO affects OMV formation and secretion of gingipains. The activity of LptO is debated, originally proposed as a lipid A deacylase and recently proposed to instead be a lipid A 1-phosphatase 90, 91 . However, mutants with null alleles of lptO produce 50% less OMVs and secrete fewer proteins recognized by a type IX secretion system, supporting the role of LptO in these processes [90] [91] [92] . Finally, a mechanism of recruitment of the disease-associated protein peptidylarginine deiminase (PPAD) to LPS and OMVs was recently proposed. PPAD citrullinates host proteins 93 and is implicated in the autoimmune disease rheumatoid arthritis 94, 95 . PPAD is produced in soluble and LPS-bound forms, but a single amino acid change (Gln373 to Lys) in PPAD reduces LPS binding 96, 97 . Further work is needed to clarify how PPAD and other P. gingivalis OMV proteins associate with LPS. Another excellent example of how LPS structure influences OMV formation is the interaction of the quorum sensing molecule Pseudomonas quinolone signal of P. aeruginosa with lipid A 98 . Pseudomonas quinolone signal binds to the 4′-phosphate group of LPS, inserts itself partially into the membrane and induces curvature that stimulates OMV formation 98, 99 . Thus, this signalling molecule stimulates its own secretion into the environment.
Recently, chemical alterations to LPS have also been implicated in stimulation of OMV formation. Specifically, deacylation of LPS by overexpression of PagL increased both the number and the size of OMVs released by S. Typhimurium 100 (Fig. 3d) . Another study 101 also recently found that shifts between neutral and high-Mg 2+ -concentration media and acidic and lowMg 2+ -concentration media activated PhoPQ and PmrAB and increased the number and size of released OMVs. Aminoarabinose-modified and phosphoethanolaminemodified LPSs were under-represented, whereas hepta-acylated LPS (from PagP activity) was enriched in OMVs 101 . The co-occurrence of increased size and number of OMVs with enrichment of PagP-modified LPS could indicate that this modification also stimulates OMV production 101 . It was proposed that exclusion of certain LPS forms from OMVs, such as aminoarabinosemodified and phosphoethanolamine-modified LPS on PhoPQ and PmrAB activation, could be a mechanism for quickly enriching these modified forms in the outer membrane during environmental transitions 101 . These two connections between LPS modifications and OMVs raise many questions for cell envelope biogenesis and bacterial pathogenesis. Under what conditions are PagP and PagL upregulated to stimulate OMV formation and under what conditions are they upregulated to alter fluidity of the outer membrane by altering LPS acylation? Does the selective secretion of PagL-modified and PagP-modified forms of LPS in OMVs, which are less immunostimulatory, affect the host immune response to pathogenic bacteria? As discussed above, aminoarabinose-modified LPS inhibits the activities of LpxR and PagL; does this function as a regulatory feedback to decrease OMV formation once the LPS content of the outer membrane has been appropriately adjusted?
Inhibitors of LPS biogenesis
There has been much focus on developing inhibitors of LPS biogenesis and modification as they are ideal targets for antimicrobial treatment due to their uniqueness to bacteria, their essential nature and their role in virulence. Inhibitors have been explored for many of the enzymes involved in Kdo synthesis and the Raetz pathway 102, 103 ( Fig. 4) , focusing on enzymatic steps that are essential in most Gram-negative bacteria. The most promising inhibitors of LPS synthesis have been LpxC inhibitors due to their broad activity, reviewed thoroughly by Erwin 104 . However, recent findings have suggested there should be more focus on the development of inhibitors of LpxK and LpxH because, even in bacteria that can grow in the absence of LPS, inhibition of these enzymes results in the build-up of toxic intermediates 105, 106 . Such inhibitors could be particularly important for treating infections with pathogenic A. baumannii strains, which are commonly multidrug resistant and can survive in the absence of LOS (Box 1). Inhibitors of the later steps in lipid A and LPS synthesis could still prove useful in combination with drugs that normally cannot permeate the asymmetric outer membrane. The most recent studies targeting LPS synthesis have attempted to increase the efficacy of LpxC inhibitors 107 , have identified compounds that target LpxA through virtual screening methods 108 and have developed new high-throughput screening strategies 109, 110 for other Lpx enzymes (for example, LpxH).
Compounds that target transporters of LPS have also been explored as antimicrobials (Fig. 4) . Two classes of inhibitors were recently reported that target MsbA 2 . The first are quinolone-like compounds that bind to the transmembrane pocket of MsbA 2 and lock it in an LPSbound, inward-facing conformation 111 . These inhibitors potently inhibit growth of E. coli and K. pneumoniae but are less effective against MsbA 2 from P. aeruginosa, indicating that they might lead to narrow-range antimicrobials 111 . Another group also recently reported a class of compounds that inhibit MsbA 2 in A. baumannii 112 . The compounds appear to stimulate wasteful ATP hydrolysis by MsbA 2 that is uncoupled from LPS flipping 112 . A compound that affects coupling of ATP hydrolysis and LPS transport has also been discovered for the Lpt complex (Fig. 4) . The already well-described DNA gyrase inhibitor novobiocin was capable of binding to the Lpt machinery 113 ; however, binding increased LPS transport instead of inhibiting it 113 . Although novobiocin does not inhibit LPS transport, it could be a good starting point for the rationale design of compounds targeting Lpt. Furthermore, novobiocin and novobiocin derivatives, including compounds unable to inhibit DNA gyrase, were found to work synergistically with polymyxins in strains that are naturally sensitive to polymyxins 114 . These findings indicate that increased LPS transport potentiates the effect of polymyxins 114 and that combination therapies could be used to reduce the amount of polymyxin needed to treat bacterial infections. However, in strains with modified lipid A, novobiocin does not significantly synergize with polymyxin (personal communication, Trent laboratory), indicating that a combination therapy would have limitations in the clinic.
Three other compounds target the periplasmic domains of the Lpt transporter (Fig. 4) . LptC, LptA and the N-terminus of LptD contain homologous β-jellyroll domains that interact head-to-tail by strand addition to bridge the periplasm 9 . LPS molecules travel across the Lpt periplasmic bridge with acyl chains protected in a hydrophobic groove formed by the β-jellyroll domains 9 .
A class of macrocyclic peptidomimetics specifically inhibited LPS transport in Pseudomonas spp. by binding to the periplasmic domain of LptD 115, 116 . These peptidomimetics are proposed to block LPS as it traverses the periplasm 115, 117 . In addition, two previously discovered antibacterial compounds, thanatin and IMB-881, were recently found to disrupt assembly of the LPS transporter subunits (Fig. 4) . Thanatin can bind to the periplasmic domain of LptD and LptA 118 . Binding of thanatin to LptA occurs at the N-terminus β-strand in a way hypothesized to block interactions between LptA and LptC 118 . IMB-881 blocked interactions between LptA and LptC in a screen using a yeast two-hybrid system and subsequent surface plasmon resonance experiments 119 . Thanatin and IMB-881 have antibacterial activity against many Gramnegative bacteria 118, 119 and could be developed into useful wide-spectrum antimicrobials.
Finally, inhibitors that block the expression or directly inhibit the enzymatic activity of lipid A-modifying enzymes have been reported (Fig. 4) . Since LPS modifications are crucial for the virulence of many pathogens and antibiotic resistance, these compounds could be used to directly treat many bacterial infections or in combination therapy to potentiate polymyxins. Inhibitors were discovered that downregulated PmrAB and reduced lipid A modifications in A. baumannii and K. pneumoniae 120 . Indeed, these compounds potentiated polymyxins 120 . Substrate mimics have also been reported that can directly inhibit ArnT, which is expected to have a similar effect 121 . These compounds could prove to be useful for treating infections with bacteria with PmrABmediated resistance to polymyxins. However, they would be unable to reverse polymyxin resistance arising from the plasmid-encoded homologues of eptA (mcr genes), whose expression is PmrA independent. No compounds have yet been identified that target EptA, but the recent full-length structure of the enzyme could serve as a starting point for rational design of inhibitors 122 . Altogether, much work has been devoted to designing and identifying compounds that inhibit LPS biogenesis and modification. More work is needed to explore which of these inhibitors has potential as a clinical antimicrobial or to identify new promising compounds.
Conclusions and future directions
We have touched on the striking diversity of chemical alterations of LPS that pathogenic bacteria use and the associated physiological consequences. Yet, it is clear that we do not have a complete story of all the biological processes in which LPS is involved, and many open questions remain. It is still unclear why LPS is essential in almost all Gram-negative bacteria. Further work on bacteria able to survive in the absence of LPS, such as A. baumannii, will provide clues to the additional roles that LPS has as a major constituent of the outer membrane. Also, from a bacterial physiology standpoint, LPS biogenesis is a complex process; LPS is synthesized on the cytoplasmic side of the inner membrane, transported across multiple membranes and modified in all compartments of the cell. Although the major synthetic enzymes and transporters have been identified in many bacteria, how synthesis and transport are coordinated to ensure efficient assembly of the bacterial outer membrane is unknown. Do LPS synthetic enzymes form large synthome complexes? In bacteria that constitutively modify LPS, what are the checkpoints to ensure modifications have occurred (Box 3)? Furthermore, LPS biogenesis and its modification likely have connections to other cellular processes that have yet to be discovered. For example, the LPS modification enzyme LpxT uses undecaprenyl pyrophosphate as a phosphate donor and contributes to recycling of this carrier molecule 123 . Conceptually, this also opens up the possibility that undecaprenyl pyrophosphate could function as phosphate donor for other processes in the periplasm, where no ATP is available. In addition, EptC in C. jejuni is a phosphoethanolamine transferase that remarkably modifies lipid A, a heptose sugar of the core oligosaccharide, N-linked glycans of proteins and the rod of the C. jejuni flagellum 124, 125 . Many bacteria contain multiple homologues of phosphoethanolamine transferases; how many of these are involved in LPS modifications, protein modifications or both? LPS modification enzymes could have a larger role in regulating the activity of cell envelope proteins.
It has also become apparent that LPS has crucial roles in interactions between bacteria and other organisms. We have briefly reviewed how LPS can stimulate the human immune system, and both commensal and To ensure lipopolysaccharide (lPS) synthesis is complete before transport, the inner membrane flippase MsbA 2 transports hexa-acylated lPS more efficiently than tetra-acylated lPS 144 . The molecular mechanism for selectively is still unclear, but mutations that alter a proline in either transmembrane 1 or transmembrane 2 of msbA resulted in increased transport of lipid Iv A in strains with disrupted 3-deoxy-d-mannooct-2-ulosonic acid (Kdo) synthesis 145 . Recently obtained cryo-electron microscopy structures of msbA 2 before and after flipping suggest a trap and flip model: lipid A binds in a deep cavity of msbA 2 (see the Protein Data Bank (PDB) 5Tv4 structure in the figure), which allows it to translocate to the outer leaflet of the inner membrane before flipping 146 . ATP hydrolysis then causes transmembrane rearrangement to flip and release lipid A 146 . Selectivity for hexa-acylated lipid A likely occurs before the 'trap' state as it would be energetically unfavourable to release lipid A back into the inner leaflet once this step is reached.
many modifications of lPS and attachment of o antigen, if present, to the core oligosaccharide occur at the periplasmic leaflet of the inner membrane 3 . Presumably, it would be advantageous for desired core-lipid A modifications and O-antigen addition to occur before transport by the lpt machinery. Work in Burkholderia cenocepacia and Escherichia coli suggests that the lpt machinery recognizes charges at the 1 and 4′ positions of lipid A to control which molecules are transported. In B. cenocepacia, lPS is predominantly aminoarabinose-modified, and this modification is essential for viability 147 . B. cenocepacia strains that produce unmodified, negatively charged lipid A are viable only with a compensatory mutation that alters an Asp residue to a neutral His residue in the substrate cavity of LptFG (coloured red on LptG in the PDB 5X5Y structure), suggesting a charge interaction between the transporter and the substrate (Kdo 2 -lipid A from PDB 3FXI shown in the figure) 148 . Further analysis of this residue in LptG suggested it might have coevolved with the LPS form in the respective species to accommodate the charge of the 1 and 4′ positions of lipid A produced in different Gram-negative bacteria 149 . In E. coli, LptG contains a positively charged residue at this site, and lipid A is predominantly unmodified at the 1-phosphate and the 4′-phosphate. Furthermore, mutations in E. coli that alter this residue in LptG to have a negative charge conferred defects that could be suppressed by mutations that increased the amount of lipid A modified with positively charged phosphoethanolamine 149 . These findings suggest that charge-charge interactions between the glucosamine disaccharide backbone of lipid A and LptG are a way to select which form of LPS is transported to the outer membrane. Recent structural and functional studies of lptB 2 FG in complex with LptC have demonstrated that the single transmembrane domain of LptC also forms part of the lPS-binding cavity, specifically at the point at which lPS enters the cavity 150, 151 . Furthermore, the transmembrane domain of LptC regulates the ATPase activity of the Lpt transporter, suggesting a role in coordinating ATP hydrolysis and LPS movements 150, 151 . If and how LptC responds to modified forms of LPS during transport remains to be seen. For B. cenocepacia, gating which lPS is transported is a convenient way to ensure that a constitutive modification of lipid A occurs. However, it is clear that not all bacteria with constitutive modifications of lPS use similar regulatory mechanisms because constitutive modifications are not essential in many organisms, including Helicobacter pylori. pathogenic bacteria have been implicated in immune system development and, thereby, the incidence of asthma, allergies and autoimmune diseases. Many studies have shown that the rate of autoimmune diseases is increased in regions with improved sanitation and reduced childhood exposure to infectious agents 126 . Recently, in a study that followed the development of the gut microbiota in infants from various regions, high abundance of members of the phylum Bacteroidetes in the gut during infancy was correlated with high incidence of autoimmune diseases 127 . Members of the phylum Bacteroidetes produce modified LPS that is less immunostimulatory than LPS from other gut bacteria, suggesting that LPS stimulation of the immune system is crucial during development 127 . Finally, it is important to note that changes in lipid A and LPS structure also affect interactions between bacteria and plants, with a number of LPS-modifying enzymes characterized in Rhizobium species 128 . Our concepts of how bacteria contribute to the development of complex organisms are evolving, and LPS will probably have a major role in many more aspects of these processes.
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